Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pentachlorophenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.38 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.33 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.83 |
| ▸ | TSHR | P16473 | 7/20 | 0.83 |
| ▸ | HPGD | P15428 | 7/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentachlorophenol SCHEMBL21647360 | 0.96 | HSD17B10 (0.91) | HSD17B10TSHRHPGDALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL3260733 | 0.96 | HSD17B10 (0.91) | HSD17B10TSHRHPGDALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL29686548 | 0.96 | HSD17B10 (0.91) | HSD17B10TSHRHPGDALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL1639406 | 0.96 | HSD17B10 (0.91) | HSD17B10TSHRHPGDALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL15486969 | 0.92 | HPGD (0.83) | HSD17B10TSHRHPGDALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL9824615 | 0.92 | HSD17B10 (0.83) | HSD17B10TSHRHPGDALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL3690606 | 0.92 | HSD17B10 (0.83) | HSD17B10TSHRHPGDALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL8726574 | 0.92 | HSD17B10 (0.83) | HSD17B10TSHRHPGDALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL4689930 | 0.92 | HSD17B10 (0.83) | HSD17B10TSHRHPGDALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL10440272 | 0.92 | HSD17B10 (0.83) | HSD17B10TSHRHPGDALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2874980-B1 | IMPROVED PROCESS FOR PREPARATION OF 2,3-DIHYDROXY BENZONITRILE | LAURUS LABS LTD (IN) | 2017-11-22 | — | — | EP | claimed |
| US-9567292-B2 | Process for preparation of 2,3-dihydroxy benzonitrile | LAURUS LABS PRIVATE LIMITED (IN) | 2017-02-14 | — | — | US | claimed |
| US-20150175532-A1 | PROCESS FOR PREPARATION OF 2,3-DIHYDROXY BENZONITRILE | LAURUS LABS PRIVATE LIMITED (IN) | 2015-06-25 | — | — | US | claimed |
| EP-2874980-A1 | IMPROVED PROCESS FOR PREPARATION OF 2,3-DIHYDROXY BENZONITRILE | Laurus Labs Private Limited (IN) | 2015-05-27 | — | — | EP | claimed |
| WO-2014013512-A1 | IMPROVED PROCESS FOR PREPARATION OF 2,3-DIHYDROXY BENZONITRILE | LAURUS LABS PRIVATE LIMITED (IN) | 2014-01-23 | — | — | WO | claimed |
| EP-0395065-A1 | Tetrahydroisoquino [2,1-c] [1,3] benzodiazepines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-10-31 | — | — | EP | claimed |
| EP-0323897-A2 | Preparation of 4,4'-diphenoxybenzophenone | RAYCHEM CORPORATION (a California corporation) (US) | 1989-07-12 | — | — | EP | claimed |
| JP-8268946-A | — | — | None | — | — | JP | disclosed |
| US-10717727-B2 | Pyridinium compounds | TORRENT PHARMACEUTICALS LIMITED (IN) | 2020-07-21 | — | — | US | disclosed |
| US-20190169175-A1 | NOVEL PYRIDINIUM COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2019-06-06 | — | — | US | disclosed |
| US-10233175-B2 | Pyridinium compounds | TORRENT PHARMACEUTICALS LIMITED (IN) | 2019-03-19 | — | — | US | disclosed |
| US-20180118728-A1 | NOVEL PYRIDINIUM COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-05-03 | — | — | US | disclosed |
| EP-3280711-A1 | NOVEL PYRIDINIUM COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-0296589-A2 | Non-aqueous electrochemical cell | Hitachi Maxell Ltd. (JP) | 1988-12-28 | — | — | EP | disclosed |
| EP-0291542-A1 | Hydraulic fluid | ETHYL CORPORATION (US) | 1988-11-23 | — | — | EP | disclosed |
| EP-0286279-A1 | Synthesis of substituted pyrazoles | ELI LILLY AND COMPANY (US) | 1988-10-12 | — | — | EP | disclosed |
| EP-0282077-A2 | Pyridyloxy derivatives | FUJIREBIO KABUSHIKI KAISHA (JP) | 1988-09-14 | — | — | EP | disclosed |
| EP-0260153-A2 | Cyclohexylphenylpyridazines | Chisso Corporation (JP) | 1988-03-16 | — | — | EP | disclosed |
| EP-0252474-A2 | Hydrazine derivatives | AMERICAN CYANAMID COMPANY (US) | 1988-01-13 | — | — | EP | disclosed |
| EP-0222577-A2 | Crystalline cephalosporin monohydrate | ELI LILLY AND COMPANY (US) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118728-A1 | NOVEL PYRIDINIUM COMPOUNDS | CYP3A5, MAPT, PLPBP | GLA 4489/4885HSP90AA1 4802/4885TTR 182/4885 |
| US-20190169175-A1 | NOVEL PYRIDINIUM COMPOUNDS | CYP3A5, MAPT, PLPBP | GLA 4489/4885HSP90AA1 4802/4885TTR 182/4885 |
| US-10717727-B2 | Pyridinium compounds | CYP3A5, PLPBP, PDXK | GLA 4395/4885HSP90AA1 4795/4885TTR 179/4885 |
| US-10233175-B2 | Pyridinium compounds | CYP3A5, PLPBP, PDXK | GLA 4395/4885HSP90AA1 4795/4885TTR 179/4885 |
| US-20150175532-A1 | PROCESS FOR PREPARATION OF 2,3-DIHYDROXY BENZONITRILE | HAAO, HPD, HAO2 | GLA 3314/4885HSP90AA1 1428/4885TTR 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.